Arrhythmia models for drug research: Classification of antiarrhythmic drugs

Journal of Pharmacological Sciences

Volumn 103, Issue 4, 2007, Pages 333-346

  Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Antiarrhythmic drug; Arrhythmia model; Classification; Ion channel; Proarrhythmic potential of drugs

Indexed keywords

20 ETHYL 1ALPHA,16BETA DIMETHOXY 14ALPHA (4 METHOXYBENZOYLOXY)ACONITANE 8,13 DIOL; 4 (5H DIBENZO[A,D]CYCLOHEPT 5 YLIDENE) 1 [3 (3 METHOXY 2 NITROPHENYL) 2 PROPENYL]PIPERIDINE; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 ISOPROPYL 3,8,N1,N1 TETRAMETHYL N2 (2 PYRIDYLMETHYL) 1 AZULENECARBOXAMIDINE; 6 (3 DIMETHYLAMINOPROPIONYL)FORSKOLIN; ADRENALIN; AMIODARONE; BIDISOMIDE; BISARAMIL; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CIBENZOLINE; DIGITALIS; DILAZEP; DISOPYRAMIDE; ETACIZINE; FLECAINIDE; GALLOPAMIL; HALOTHANE; ISOPRENALINE; MEXILETINE; OTENZEPAD; PINDOLOL; PROCAINAMIDE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL BLOCKING AGENT; TOCAINIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ZATEBRADINE;

CORONARY ARTERY LIGATION; DRUG ACTIVITY; DRUG BINDING; DRUG CLASSIFICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG RESEARCH; ELECTROSTIMULATION; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; IN VIVO STUDY; NONHUMAN; REPERFUSION INJURY; REVIEW; TORSADE DES POINTES;

EID: 34247333050     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.CRJ06013X     Document Type: Review

References (108)

1. Christ T, Ravens U. Do we need new antiarrhythmic compounds in the era of implantable cardiac devices and percutaneous ablation? Cardiovasc Res. 2005;68:341-343.
2. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
3. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation. 1991;84:1831-1851.
4. Vaughan Williams EM. Classifying antiarrhythmic actions: by facts or speculations. J Clin Pharmacol. 1992;32:964-977.
5. Hashimoto K, Haruno A, Matsuzaki T, Sugiyama A, Akiyama K. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness? Cardiovasc Drugs Ther. 1991;5:805-818.
6. Hashimoto K, Xue YX, Chen JG, Akie Y, Eto K, Ni C, et al. Effects of class III antiarrhythmic drugs on ventricular arrhythmias in dogs. Exp Clin Cardiol. 1997;2:25-29.
7. + exchange inhibitors. Eur Heart J Suppl. 1999; 1 Suppl K:K31-K37.
8. Hashimoto K, Nagasawa E, Zhu BN. Na/H exchange and arrhythmia. In: Dhalla NS, Takeda N, Singh M, Lukas A, editors. Myocardial ischemia and preconditioning. Boston: Kluwer Academic Publishers; 2003, p. 389-397.
9. Harris AS. Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation. 1950;1:1318-1328.
10. Hashimoto K, Satoh H, Shibuya T, Imai S. Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia. J Pharmacol Exp Ther. 1982;223:801-810.
11. Maxwell MP, Hearse DJ, Tellon DM. Species variation in the coronary collateral circulation during regional myocardial ischemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res. 1987;21:737-746.
12. Wu ZJ, Awaji T, Hirasawa A, Motomura S, Hashimoto K. Effects of a new class I antiarrhythmic drug bidisomide on canine ventricular arrhythmia models. Mol Cell Biochem. 1993;119:159-169.
13. Hashimoto K, Tsukada T, Matsuda H, Matsubara I, Imai S. Antiarrhythmic effect of oxprenolol on halothane-epinephrine and coronary ligation induced ventricular arrhythmias in beagle dogs. Jpn J Pharmacol. 1978;28:535-544.
14. Hashimoto K, Tsukada T, Matsuda H, Matsubara I, Imai S. Antiarrhythmic effects of bupranolol against canine ventricular arrhythmias induced by halothane-adrenaline or two-stage coronary ligation. J Cardiovasc Pharmacol. 1979;1:205-217.
15. Hashimoto K, Komori S, Ishii M, Kamiya J. Effective plasma concentrations of aprindine in canine ventricular arrhythmias. J Cardiovasc Pharmacol. 1984;6:12-19.
16. Hashimoto K, Ishii M, Komori S. Antiarrhythmic plasma concentrations of mexiletine on canine ventricular arrhythmias. J Cardiovasc Pharmacol. 1984;6:213-219.
17. Ishii K, Komori S, Satoh H, Ohta T, Motomura S, Hashimoto K. [Effects of N-696, a new β-blocking agent, on canine experimental arrhythmias.] Folia Pharmacol Jpn (Nihon Yakurigaku Zasshi). 1984;84:259-266. (text in Japanese with English abstract)
18. Hashimoto K, Ishii M, Komori S, Mitsuhashi H. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165. Heart Vessels. 1985;1:29-35.
19. Ishii M, Komori S, Hashimoto K. [Effects of pindolol on canine experimental arrhythmias.] Coronary. 1985;2:103-108. (in Japanese)
20. Mitsuhashi H, Akiyama K, Hashimoto K. [Effects of new antiarrhythmic drugs, AFD-21 and AFD-19 on canine ventricular arrhythmias.] Folia Pharmacol Jpn (Nihon Yakurigaku Zasshi). 1986;88:167P. (in Japanese)
21. Hashimoto K, Akiyama K, Mitsuhashi H. Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias. J Cardiovasc Pharmacol. 1987;9:148-153.
22. Mitsuhashi H, Akiyama K, Hashimoto K, Sawa Y, Hatori Y. Antiarrhythmic effects of a new drug, E-0747, on canine ventricular arrhythmia models. Jpn J Pharmacol. 1987;44:155-162.
23. Mitsuhashi H, Hashimoto K. Antiarrhythmic profile of a new class 1 drug, AHR 10718, on canine atrial and ventricular arrhythmia models. Jpn J Pharmacol. 1988;46:349-358.
24. Hashimoto K, Watanabe K, Sugiyama A. Antiarrhythmic plasma concentrations of pirmenol on canine ventricular arrhythmias. Jpn J Pharmacol. 1988;48:273-282.
25. Matsuzaki T, Haruno A, Sugiyama A, Motomura S, Hashimoto K. [Effects of AFD-21 and AFD-19 on canine coronary ligation arrhythmia.] Folia Pharmacol Jpn (Nihon Yakurigaku Zasshi). 1988;92:36 P. (in Japanese)
26. Hashimoto K, Akiyama K, Mitsuhashi H. Antiarrhythmic effect of a new class 1 antiarrhythmic drug, nicainoprol, on canine ventricular arrhythmias. Jpn J Pharmacol. 1989;49:245-254.
27. Hashimoto K, Ishii M, Watanabe K. Relationships between ventricular arrhythmias and plasma concentrations of ME3202 (CM7857) in dogs. J Cardiovasc Pharmacol. 1989;14:121-126.
28. Akiyama K, Hashimoto K. Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models. Jpn Heart J. 1989;30:487-495.
29. Hashimoto K, Matsuzaki T, Haruno A. Antiarrhythmic plasma concentrations of NIK-244 on canine ventricular arrhythmias. J Cardiovasc Pharmacol. 1989;14:892-898.
30. Hashimoto K, Watanabe K, Mitsuhashi H. Antiarrhythmic effect of a new class 1 antiarrhythmic drug, AN-132, on ventricular arrhythmias in beagles. Cardiovasc Drugs Ther. 1989;3:683-690.
31. Hashimoto K, Watanabe K, Mochizuki S, Tomiyama A. Effects of KT-362, a new Na and Ca influx and Ca release inhibitor, on canine ventricular arrhythmias. Jpn J Pharmacol. 1989;51:475-482.
32. Hashimoto K, Sugiyama A, Haruno A, Matsuzaki T, Hirasawa A. Effects of a new antiarrhythmic drug TYB-3823 on canine ventricular arrhythmia models. J Cardiovasc Pharmacol. 1991;17:336-342.
33. Hirasawa A, Haruno A, Matsuzaki T, Hashimoto K. Effects of a new antiarrhythmic drug, SD-3212, on canine ventricular arrhythmia models. Jpn Heart J. 1992;33:851-861.
34. Haruno A, Hashimoto K. Antiarrhythmic effects of bisaramil in canine models of ventricular arrhythmia. Eur J Pharmacol. 1993;233:1-6.
35. Nakamura M, Xue YX, Eto K, Hashimoto K. Antiarrhythmic effects of optical isomers of disopyramide on canine ventricular arrhythmias. J Cardiovasc Pharmacol. 1996;27:368-375.
36. Vanhoutte F, Vereecke J, Carmeliet E, Verbeke N. Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:662-673.
37. Xue YX, Arita J, Aye NN, Hashimoto K. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide. Naunyn Schmidebergs Arch Pharmacol. 1998;358:649-656.
38. Arita J, Xue YX, Aye NN, Fukuyama K, Wakui Y, Niitsu K, et al. Antiarrhythmic effects of an aconitine-like compound, TJN-505, on canine arrhythmia models. Eur J Pharmacol. 1996;318:333-340.
39. 2-(2-pyridylmethyl)-5-isopropyl- 3,8-dimethylazulene-1-carboxamidine. Arzneimittelforschung. 1997;47:810-815.
40. Takahara A, Hirasawa A, Dohmoto H, Shoji M, Yoshimoto R, Sugiyama A, et al. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models. Jpn J Pharmacol. 2001;87:21-26.
41. Awaji T, Hashimoto K. Antiarrhythmic effects of combined application of class I antiarrhythmic drugs; Addition of low-dose mexiletine-enhanced antiarrhythmic effects of disopyramide and aprindine in various-rate canine ventricular tachycardias. J Cardiovasc Pharmacol. 1993;21:960-966.
42. Kawamura K, Kodama I, Toyama J, Hayashi H, Saito H, Yamada K. Combined application of class I antiarrhythmic drugs cause "additive" or "synergic" sodium channel block in cardiac muscles. Cardiovasc Res. 1990;24:925-931.
43. 2+ channel blocker, AH-1058, assessed in canine arrhythmia models. Eur J Pharmacol. 2000;398:107-112.
44. 2+ channel blocker in models of ventricular arrhythmia in dogs. Eur J Pharmacol. 1993;231:363-370.
45. Mitsuhashi H, Akiyama K, Hashimoto K. Effects of betaxolol, a new beta 1 selective blocker, on canine ventricular arrhythmias. Jpn J Pharmacol. 1987;43:179-185.
46. Hashimoto K, Haruno A, Matsuzaki T, Hirasawa A, Awaji T, Uemura Y. Effects of a new class III antiarrhythmic drug (E-4031) on canine ventricular arrhythmia models. Asia Pacific J Pharmacol. 1991;6:127-137.
47. XueYX, Eto K, Akie Y, Hashimoto K. Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models. Jpn J Pharmacol. 1996;70:129-138.
48. Chen JG, Xue YX, Eto K, Ni C, Hashimoto K. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. J Cardiovasc Pharmacol. 1996;28:576-584.
49. Xue YX, Tanabe S, Nabuchi Y, Hashimoto K. Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular arrhythmia models. J Cardiovasc Pharmacol. 1998;32:239-247.
50. Awaji T, Wu ZJ, Hashimoto K. Acute antiarrhythmic effects of intravenously administered amiodarone on canine ventricular arrhythmia. J Cardiovasc Pharmacol. 1995;26:869-878.
51. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol. 1999;84(9A):20R-28R.
52. Hashimoto K, Haruno A, Hirasawa A. [Effects of milrinone on canine experimental arrhythmias.] Coronary. 1990;7:445-450. (in Japanese)
53. Hashimoto K, Mitsuhashi H. Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias. Br J Pharmacol. 1986;88:915-921.
54. Wu Z, Awaji T, Abe H, Motomura S, Hashimoto K. Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias. Jpn J Pharmacol. 1993;63:399-404.
55. Hirasawa A, Awaji T, Hosono M, Haruno A, Hashimoto K. Effects of a new forskolin derivatives, NKH477, on canine ventricular arrhythmia models. J Cardiovasc Pharmacol. 1993;22:847-851.
56. 2+ sensitizer, on ventricular arrhythmias and membrane ionic currents. Eur J Pharmacol. 1996;98:247-256.
57. Furukawa Y, Xue YX, Chiba S, Hashimoto K. Effects of zatebradine on ouabain-, two-stage coronary ligation- and epinephrine-induced ventricular tachyarrhythmias. Eur J Pharmacol. 1996;300:203-210.
58. Naito H, Furukawa Y, Hashimoto K. Effects of a cardioselective M2 receptor antagonist, AF-DX 116, on ventricular arrhythmias in dogs. Heart Vessels. 1997;12:229-233.
59. Hashimoto K. Electrophysiological mechanisms for digitalis arrhythmias. Jpn Circ J. 1976;40:1451-1455.
60. Roden DM. Antiarrhythmic drugs. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The pharmacological basis of therapeutics. 11th ed. McGraw-Hill; 2006. p. 899-932.
61. Glitsch HG. Electrophysiology of the sodium-potassium-ATPase in cardiac cells. Physiol Rev. 2001;81:1791-1826.
62. Hashimoto K, Shibuya T, Satoh H, Imai S. Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations. Jpn Circ J. 1983;47:92-97.
63. Sugiyama A, Xue YX, Hagihara A, Saitoh M, Hashimoto K. Characterization of magnesium sulfate as an antiarrhythmic agent. J Cardiovasc Pharmacol Ther. 1996;1:243-254.
64. 2+ exchange inhibitor, on ventricular arrhythmias in the in vivo dogs. Eur J Pharmacol. 2005;506:249-255.
65. Komori S, Ishii M, Hashimoto K. Antiarrhythmic effects of coronary vasodilators on canine ventricular arrhythmia models. Jpn J Pharmacol. 1985;38:73-82.
66. Hashimoto K, Mitsuhashi H, Nakamura T, Akiyama K. Antiarrhythmic effects of possible anti-ischemic drugs. Yamanashi Med J. 1986;1:1-10.
67. Hashimoto K, Mitsuhashi H, Nakamura T, Akiyama K. Antiarrhythmic effects of possible anti-ischemic drugs. In: Szekeres L, Papp JGy, editors. Proc 4th Cong Hung Pharmacol Soc, Budapest 1985, Vol 1 Sec 1, Pharmacological protection of the myocardium; 1985. p. 25-31.
68. Haruno A, Hashimoto K. Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. Jpn J Pharmacol. 1995;68:95-102.
69. Hashimoto K. Electrophysiological correlates of antiarrhythmic effects of drugs and pharmacokinetic principles examined using canine ventricular arrhythmias. In: Papp JGy, editor. Cardiovascular pharmacology '87. Budapest: Academiai Kiado; 1987. p. 79-93.
70. + exchange inhibitor, on ventricular arrhythmias in animal hearts. Eur J Pharmacol. 1996;317:309-316.
71. 2+ exchange inhibitor, does not suppress ischemia/reperfusion arrhythmias nor digitalis arrhythmias in dogs. Jpn J Pharmacol. 2002;90:229-235.
72. Hashimoto K, Hashimoto K. The mechanism of sensitization of the ventricle to epinephrine by halothane. Am Heart J. 1972;83:652-658.
73. Noda Y, Hashimoto K. Development of a halothane-adrenaline arrhythmia model using in vivo guinea pigs. J Pharmacol Sci. 2004;95:234-239.
74. Shibuya T, Hashimoto K, Imai S. Effective plasma concentrations of antiarrhythmic drugs against sustained halothane-adrenaline arrhythmia in dogs. J Cardiovasc Pharmacol. 1983;5:538-545.
75. V(s) blocker, on canine ventricular arrhythmia models. Eur J Pharmacol. 1999;376:27-35.
76. Hashimoto K, Xue YX, Aye NN, Chino D. Worsening of canine adrenaline arrhythmias by class III K channel blockers. J Cardiovasc Pharmacol. 1999;34 Suppl 4:S39-S42.
77. Xue YX, Yamada C, Aye NN, Hashimoto K. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias. Br J Pharmacol. 1998;124:1712-1718.
78. + channel inactivation prolongs QT interval and aggravates adrenaline-induced arrhythmias. Jpn J Pharmacol. 2001;86:114-119.
79. Miyamoto S, Zhu B-M, Teramatsu T, Aye NN, Hashimoto K. QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide. Eur J Pharmacol. 2000;400:263-269.
80. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effect of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmias. Jpn J Pharmacol. 1992;58:107-115.
81. Ogawa S, Mitamura H, Katoh H. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias in comparison with conventional class I drugs. Cardiovasc Drugs Ther. 1993;7 Suppl 3: 621-626.
82. Kigwell GA, Gonzales MD. Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects. J Cardiovasc Pharm. 1993;21:621-632.
83. Karagueuzian HS, Mandel WJ. Electrophysiologic mechanisms of ischemic ventricular arrhythmias. In: Mandel JW, editor. Cardiac arrhythmias. Their mechanisms, diagnosis, and management. Philadelphia: Lippincott; 1987. p. 452-474.
84. Hashimoto K, Haruno A, Hirasawa A, Awaji T, Xue YX, Wu ZJ. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. Jpn J Pharmacol. 1995;68:1-9.
85. Komori S, Sano S, Li BH, Matsumura K, Naitoh A, Mochizuki S, et al. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide. Heart Vessels. 1995;10:7-11.
86. Clark C, Foreman MI, Kane KA, McDonald FM, Parratt JR. Coronary artery ligation in anaesthetised rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods. 1980;3:357-368.
87. Nagasawa Y, Chen J, Hashimoto K. Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation /reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs. J Pharmacol Sci. 2005;97:393-399.
88. Chen J, Nagasawa Y, Zhu B-M, Ohmori M, Harada K, Fujimura A, et al. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholestrolemic rats. J Pharmacol Sci. 2003;93:87-94.
89. + exchange inhibitor, on canine coronary occlusion/reperfusion-induced ventricular arrhythmias. J Pharmacol Sci. 2005;98:404-410.
90. + exchange inhibitor, on reperfusion ventricular arrhythmias in rat hearts. Eur J Phramcol. 1997;339:121-127.
91. Aye NN, Komori S, Hashimoto, K. Effects and interaction, of cariporide and preconditioning on cardiac arrhythmias and infarction in rat in vivo. Br J Pharmacol. 1999;127:1048-1055.
92. + exchange inhibitor, suppresses the reperfusion-induced lethal arrhythmias and "overshoot" phenomenon of creatine phosphate in situ rat heart. J Cardiovasc Pharmacol. 1999;33:116-121.
93. + exchange inhibitor, on reperfusion-induced ventricular arrhythmias in anesthetized rat. Jpn J Pharmacol. 2002;88:93-99.
94. + exchange inhibitor, KBR-9032, on cardiac ischemia-reperfusion injury in rats. Jpn J Pharmacol. 1997;73 Suppl 1:232P.
95. 3 exchange play an important role in reperfusion arrhythmias in rats? Eur J Pharmacol. 2003;460:43-50.
96. Arita J, Katahira S, Xue YX, Aye NN, Hashimoto K. Rapid pacing-induced heart failure aggravates reperfusion arrhythmias in dogs. Asia Pacific J Pharmacol. 1998;13:137-144.
97. Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol. 2000;83:1-19.
98. Kr blockade. Eur J Pharmacol. 2005;507:169-177.
99. Akie Y, Ni C, Aye NN, Xue YX, Hashimoto K. Proarrhythmic effects of four class III antiarrhythmic drugs, MS-551, sematilide, dofetilide and KCB328, examined using ambulatory ECG. Asia Pacific J Pharmacol. 2000;14:101-109.
100. Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol. 2000;169:8-16.
101. Vos MA, Verduyn SC, Gorgels APM, Lipcsei GC, Wellens HJJ. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation. 1995;91:864-872.
102. Weissenburger J, Davy J-M, Chezalviel F, Ertzbischoff O, Poirer JM, Engel F, et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther. 1991;259:871-883.
103. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y, et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn J Pharmacol. 2002;88:341-350.
104. Sugiyama A, Satoh Y, Takahara A, Nakamura Y, Shimizu-Sasamata M, Sato S, et al. Femotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. Eur J Pharmacol. 2003;466:137-146.
105. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, et al. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circulation J. 2002;66:758-762.
106. Satoh Y, Sugiyama A, Takahara A, Chiba K, Hashimoto K. Electrophysiological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J Cardiovasc Pharmacol. 2004;43:715-723.
107. Takahara A, Sugiyama A, Ishida Y, Satoh Y, Wang K, Nakamura Y, et al. Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias. Br J Pharmacol. 2006;147:634-641.
108. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. October 2005 ICH.